Table 1

Androgen receptor (AR) expression and characteristics of breast cancer women in natural menopause
AR expression
Absent Poor Moderate High
No. %b No. %b No. %b No. %b Pc
Age, yr
 < 65 29 49.2 55 49.1 57 47.5 68 42.5 0.259
 ≥ 65 30 50.8 57 50.9 63 52.5 92 57.5
BMI, kg/m2
 < 25 28 50.0 45 46.9 58 52.7 68 47.2 0.478
 25-30 18 32.1 41 42.7 34 30.9 44 30.6
 ≥ 30 10 17.9 10 10.4 18 16.4 32 22.2
Tumor size, cm
 < 2 32 55.2 74 66.7 70 58.8 112 70.9 0.080
 ≥ 2 26 44.8 37 33.3 49 41.2 46 29.1
Histology
 Infiltrating ductal carcinoma (IDC) 50 89.3 87 79.8 95 80.5 124 77.5 0.110
 Other infiltrating carcinoma 6 10.7 22 20.2 23 19.5 36 22.5
Grade
 ≤ 2 22 37.9 68 61.3 72 61.5 112 70.4 <0.001
 > 2 36 62.1 43 38.7 45 38.5 47 29.6
Axillary nodal status
 Negative 34 60.7 66 60.6 74 62.7 95 60.1 0.958
 Positive 22 39.3 43 39.4 44 37.3 63 39.9
ER status
 Negative 28 47.5 20 18.0 13 10.8 10 6.3 <0.001
 Positive 31 52.5 91 82.0 107 89.2 149 93.7
PR status
 Negative 34 57.6 42 38.2 37 30.8 36 22.6 <0.001
 Positive 25 42.4 68 61.8 83 69.2 123 77.4
HER2 statusa
 Negative 30 58.8 35 41.7 40 48.2 64 59.3 0.332
 Positive 21 41.2 49 58.3 43 51.8 44 40.7
Total 59 13.1 d 112 24.8 d 120 26.6 d 160 35.5 d

NOTES. Androgen receptor (AR) expression: absent, 0%; poor, ≥1 to 30%; moderate, >30 to 60%; high, >60%. Estrogen receptor (ER)-positive and Progesterone receptor (PR)-positive: ER and PR expression ≥10%.

aOne hundred and twenty-five (27.7%) women had missing information about HER2 status.

bColumn percentage. cChi-square test for trend. dRow percentage.

Secreto et al.

Secreto et al. BMC Cancer 2012 12:599   doi:10.1186/1471-2407-12-599

Open Data